Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 28 systematic review(s)/meta-analysis(es). ^[1-28]
• Lurasidone significantly improved the Montgomery Asberg Depression Rating Scale (MADRS) score versus placebo (-4.71, 95% credible interval (CrI) -6.98 to -2.41) and showed higher response (relative risk (RR) 0.78, 95% confidence interval (CI) 0.66 to 0.92) and remission rates (RR 0.90, 95% CI 0.83 to 0.98).
• In Clinical Global Improvement - Bipolar Disorder (CGI-BP) scores, lurasidone demonstrated greater efficacy compared to cariprazine and ziprasidone but similar outcomes to quetiapine and olanzapine.
• Lurasidone displayed superior odds of response versus cariprazine, aripiprazole, and ziprasidone and was effective in adolescents, showing significant improvements in the Positive and Negative Symptom Scale (PANSS) and Clinical Global Impression (CGI-S) scores for schizophrenia and comparable efficacy to olanzapine-fluoxetine in bipolar depression.
• Lurasidone effectively prevented mood episode recurrence when combined with mood stabilizers and had lower odds of all-cause discontinuation compared to aripiprazole and paliperidone extended release (ER).
• Lurasidone demonstrated minimal weight change (0.34 kg [95% CrI -0.22, 0.89]) relative to placebo and showed significantly less weight gain than olanzapine and quetiapine. In adolescent populations, lurasidone was associated with lower weight gain compared to other antipsychotics.
• Lurasidone had lower increases in cholesterol and triglycerides than olanzapine and quetiapine, with minimal effects on glucose and prolactin levels.
• Adverse events associated with lurasidone included a higher incidence of akathisia, nausea, and somnolence compared to placebo, with a similar safety profile to other antipsychotics in terms of extrapyramidal symptoms (EPS) and akathisia rates.
• Lurasidone was effective and well-tolerated in adolescents with schizophrenia, showing significant improvements in PANSS and CGI-S scores, and exhibited a favorable safety profile with lower weight gain compared to other antipsychotics.